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Abstract 
Background: The two main plasmodial species in French Guiana are Plasmodium vivax and Plasmodium falciparum 
whose respective prevalence influences the frequency of mixed plasmodial infections. The accuracy of their diagnosis 
is influenced by the sensitivity of the method used, whereas neither microscopy nor rapid diagnostic tests allow a 
satisfactory evaluation of mixed plasmodial infections.
Methods: In the present study, the frequency of mixed infections in different part of French Guiana was determined 
using real time PCR, a sensitive and specific technique.
Results: From 400 cases of malaria initially diagnosed by microscopy, real time PCR showed that 10.75 % of the cases 
were mixed infections. Their prevalence varied considerably between geographical areas. The presence, in equivalent 
proportions, of the two plasmodial species in eastern French Guiana was associated with a much higher prevalence of 
mixed plasmodial infections than in western French Guiana, where the majority of the population was Duffy negative 
and thus resistant to vivax malaria.
Conclusion: Clinicians must be more vigilant regarding mixed infections in co-endemic P. falciparum/P. vivax areas, 
in order to deliver optimal care for patients suffering from malaria. This may involve the use of rapid diagnostic tests 
capable of detecting mixed infections or low density single infections. This is important as French Guiana moves 
towards malaria elimination.
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Background
In the early 2000s, French Guiana was one of the most 
malaria-affected territories among the South American 
regions [1]. Between 2000 and 2009, the average yearly 
number of cases was 3920, although, the decline was 
rapid and marked thereafter to reach only 445 cases in 
2014 [2]. The dominant plasmodial species are Plasmo-
dium vivax and Plasmodium falciparum. Plasmodium 
malariae is much rarer, only representing 1 % of cases [3, 
4]. For the past 30 years, malaria transmission nearly no 
longer affects the coastal area of French Guiana [5], but it 
persists in the interior regions [6]. In these areas, where 
only 15  % of the 230,000 inhabitants of French Guiana 
live, infections were mainly observed among popula-
tions living along the Maroni River in the western part of 
French Guiana bordering Suriname, and the Oyapock in 
the eastern part bordering Brazil. Nowadays, infections 
are mainly related to mining activities [7].
The presence of P. falciparum was more frequent in 
western French Guiana, where the Maroon populations 
live. This population is resistant to P. vivax because, as 
most Africans, they do not express the Duffy antigen. 
Eastern French Guiana was mostly populated by Amer-
indians and the incidence of P. vivax is similar to that of 
P. falciparum [8]. During the 2000s, there has been an 
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increase in P. vivax malaria in eastern French Guiana and 
a decrease of P. falciparum malaria in western French 
Guiana, notably along the Maroni River [3]. Overall, the 
proportion of P. falciparum in French Guiana has thus 
decreased from 46 % of all malaria cases in 2005 to 30 % 
in 2014 [2, 9].
The specific treatment used in French Guiana depends 
on the infecting species, the severity of disease and the 
patient’s condition. Chloroquine is administered in 
uncomplicated vivax malaria, in association with pri-
maquine. For P. falciparum, artemether and lumefantrine 
(Riamet®) is employed since 2007. Thus, the identifica-
tion of the infecting plasmodial species is essential to 
select the appropriate treatment.
Although errors in species identification are rare, it is 
common to miss mixed species infections by the micro-
scopic examination of blood smears, particularly when one 
of the species is predominant in the patient’s blood, which 
is a frequent situation [10, 11]. In addition, most rapid diag-
nostic tests, and notably the one used in French Guiana 
(SD Bioline® Pf/Pan), cannot distinguish between single P. 
falciparum infections and a mixed P.  falciparum/P. vivax 
infections. This may lead to inadequate treatment, since 
misdiagnosis of a P. falciparum/P. vivax mixed infection 
as a P. falciparum infection may lead to failure to adminis-
ter primaquine and hence will lead to vivax relapses, while 
misdiagnosis of P. falciparum/P. vivax as P. vivax infection 
may lead to the use of chloroquine for resistant, potentially 
severe, P. falciparum infections. Therefore, it is important 
for clinicians to have local data on the frequency of mixed 
infections. This problem concerns areas with resistant P. 
falciparum and/or P. vivax with frequent relapses, which 
was the case in French Guiana [12, 13]. It is thus important 
to use more sensitive and discriminant techniques such as 
PCR [14–19].
In the present study, the frequency of mixed P. 
falciparum/P. vivax infections in eastern and western 
French Guiana were thus determined using real-time 
PCR and compared to microscopic results.
Methods
Samples
Between 2000 and 2008, malaria diagnoses in the health 
centres and at the Hospital were performed using thin 
and thick blood smears, and were then confirmed by an 
experienced microscopist at the Department of Para-
sitology and Mycology at the Hospital. Given the low 
prevalence of mixed infections using microscopy, PCR 
diagnosis was implemented in order to estimate the prev-
alence of mixed infections.
The study included samples from patients with clini-
cal malaria having consulted remote health centres or 
Cayenne Hospital between 2000 and 2008. Samples were 
collected for diagnostic purposes on filter paper (What-
man®) or in EDTA vacutainers, through the Cayenne 
Hospital or the National Reference Centre for Malaria, 
respectively. When filter paper was available and when 
the physician on site was informed (fast rotation of pro-
fessionals in these remote centers, with newcomers not 
aware of all ongoing protocols) the filter paper was sent 
to the Hospital where PCR was performed. Thus, whether 
a patient eventually got PCR, it was not linked to the par-
ticulars of the patient or the malaria episode leading to 
the consultation, but to the health care professional rota-
tion. Thus, this was not likely to be a recruitment bias.
Among the 400 samples collected (representing 10  % 
of French Guiana cases), 331 came from health centres 
located in the eastern part of French Guiana: Cacao, 
Saint-Georges-de-l’Oyapock, Régina, Camopi, Trois-
Sauts, and Cayenne Hospital (Fig. 1). In the latter, sam-
ples came from patients living in Cayenne or in other 
towns of central or eastern French Guiana.
The 69 other samples came from health centres 
located in the western part of French Guiana: Antec-
ume Pata, Maripasoula, Papaïchton, Grand-Santi, and 
Apatou (Fig.  1). All samples were anonymized before 
transmission.
DNA extraction
The DNA from the samples conserved on filter paper or 
at −20  °C were extracted using the DNeasy® Blood and 
Tissue Kit or the Qiaamp DNA blood kit (Qiagen, Craw-
ley, UK), as recommended by the manufacturer.
Real‑time PCR
DNA was amplified using real time PCR as described by 
Veron et al. [20]. The amplified region corresponds to the 
small 18S RNA sub-unit. The P. falciparum primer sense 
sequence was: Pf1 5′-ATTGCTTTTGAGAGGTTTTGT 
TACTTT-3′, that of the antisense primer was: Pf-2 
5′-GCTGTAGTATTCAAACACAATGAACTCAA-3′ 
and that of the probe was: Pf-probe FAM-CATAACAG 
ACGGGTAGTCAT-MGB. The size of the amplicon was 
95 pb. The sequence of the P. vivax sense primer was: 
Pv-1 5′-CGCTTCTAGCTTAATCCACA TAACTG-3′, 
that of the antisense primer was: Pv-2 5′-AATTTACTC 
AAAGTAA CAAGGACTTCCAAG-3′ and that of the 
probe was: Pv-probe VIC-CGCATTTT GCTATTATGT-
MGB. The amplicon size was 142 pb. The amplification 
and the detection of DNA were performed in duplex, 
using the PCR Applied Biosystem 7300 analytic system. 
Real-time PCR was performed in a final volume of 25 µl, 
in presence of an internal positive control (IPC) (Applied 
Biosystem, Courtaboeuf, France). Samples were analysed 
in two tubes, the first one contained P. falciparum and P. 
vivax primers and probes and the second one the internal 
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control of the absence of inhibitor, the IPC. Each reaction 
mix contained 12.5  µl of Master Mix Gene Expression 
(Applied Biosystem), 300 nM of each primer (P. falcipa-
rum and P. vivax), 150 nM of each probe (P. falciparum 
and P. vivax) and 5 µl of matrix DNA. The IPC was used 
as recommended by the manufacturer. PCR starts with a 
10-min phase at 95  °C, followed by 50 cycles of 15  s at 
95 °C and 1 min at 60 °C.
Statistical analysis
Proportions of mixed infections were compared between 
regions using the χ2 test.
Ethical consideration
The retrospective use of anonymous patient files on the 
site of patient care is authorized by the French National 
Commission on Informatics and Liberties (CNIL). All the 
human blood samples and the data collected retrospec-
tively were anonymized in a standardized case report 
form and in database.
Results
The quantities of the different plasmodia species detected 
for microscopy and real-time PCR are presented in 
Table 1. The real-time PCR results (Table 1) showed the 
Fig. 1 Distribution of mixed infections from different parts of French Guiana
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presence of 149 P. falciparum and 140 P. vivax infections 
in the eastern French Guiana and 62 P. falciparum and 6 
P. vivax infections in western French Guiana. Forty-three 
samples, within the 400 collected samples, corresponded 
to mixed P. falciparum/P. vivax infections, which repre-
sented a frequency of 10.75 %, versus 2 % in microscopy. 
Forty-two originated from Eastern French Guiana and 
only one came from the western part. The latter was an 
isolate from Maripasoula, a municipality which marks 
the end of the Maroon territory and the beginning of 
Amerindian territory. Thus, in eastern French Guiana 
the proportion of mixed infections was 12.7  % whereas 
in western French Guiana the prevalence was only 1.4 %. 
This difference was statistically significant (P  <  0.0001). 
The municipalities of Saint-Georges-de-l’Oyapock 
(n = 11), Camopi (n = 9), Trois-Sauts (n = 10), and Cay-
enne (n = 10) were the sites with the highest number of 
mixed infections observed (Fig. 1).
Mixed infections misdiagnosed by microscopy were 
only observed in eastern French Guiana. In 15 cases the 
association was diagnosed as P. vivax and in 20 cases, as 
P. falciparum (Table 1).
Discussion
Overall, mixed plasmodial infections were frequent in 
French Guiana with 10.75  % of malaria cases having 
mixed P. vivax/P. falciparum malaria. This overall figure 
however, masks a very heterogeneous situation between 
eastern, where most mixed infections came from, and 
western French Guiana, where there was only 1.4  % 
mixed infection. The incidence of P. vivax malaria is very 
low among Maroon populations, who are Duffy negative 
and the main ethnic group living on the Maroni River. 
This ethnic particularity could explain the low prevalence 
of mixed infections in western French Guiana [21, 22].
Other authors have observed that over a quarter of P. fal-
ciparum infections were in fact mixed infections [23]. Stud-
ies conducted in different endemic areas also had different 
designs often involving cross-sectional studies of exposed 
populations, and not microscopically confirmed malaria 
patients as in this study. Molecular studies from Brazil 
showed that P. falciparum mixed species were detected in 
30 % [24], 23.4 % [25] and 10 % [26] in Rondônia for the 
first two, and Apiacas, respectively. The proportion of 
mixed infections was lower in Brazil than in some studies 
from Thailand (24.2–51.6 %) [27] and Papua New Guinea 
(65.3 %) [17], and similar in Laos (23.1 %) [28].
Mixed infections have been associated with less severe 
malaria by some [29, 30] and with severe malaria [31] or 
higher fever [32] by other authors. Apart from the immu-
nologic and pathophysiologic consequences of mixed 
infections, their misdiagnosis could lead to treatment 
that is not effective against the hidden species. Thus, 
missing a hidden P. falciparum infection leads to treat-
ment with chloroquine with potential risks for the patient 
owing to the 25 % of chloroquine-resistant parasites cir-
culating in the region [33]. Conversely, when P. vivax is 
hidden, although artemisinin-based combination therapy 
(ACT) will kill P. vivax, treatment of latent hypnozoites 
with primaquine will be omitted thus leading to the risk 
of P. vivax relapses, notably as P. falciparum malaria re-
activates latent hypnozoites [13, 34, 35]. As the French 
and Brazilian Ministers of health announced in July 2015, 
malaria elimination was a common goal, the capacity to 
diagnose low density infections is capital [36]. However, 
when comparing the cases of mixed infections in 2006 
and 2007, there was a significant decrease, respectively 
18.7 and 9.8 % (p = 0.03), presumably following the over-
all incidence decrease.
PCR is much more sensitive than microscopy and rapid 
diagnostic tests, notably to detect mixed infections [14–
19]. However, the high costs of this technique are still an 
obstacle for its use in remote health centres of French 
Guiana. Nevertheless, depending on the microscopist 
experience, TDR could be a more efficient technique 
than microscopy [37] and could be applied to remote 
areas, provided it is sufficiently sensitive to detect the two 
Plasmodium species at low parasite densities.
Conclusion
Microscopy often fails to reveal mixed infections or low 
density single infections. In French Guiana, there is a 
Table 1 Microscopy and real-time PCR results
Pf/Pv the number of cases of mixed infections P. falciparum/P. vivax detected by real-time PCR for each remote health centres. The percentages of each species of 
plasmodium and mixed infections Pf/Pv were shown in parentheses
P. falciparum P. vivax Pf/Pv Total
Microscopy Q‑PCR Microscopy Q‑PCR Microscopy Q‑PCR
East 169 (51.1 %) 149 (45.0 %) 155 (46.8 %) 140 (42.3 %) 7 (2.1 %) 42 (12.7 %) 331
West 62 (89.9 %) 62 (89.9 %) 6 (8.7 %) 6 (8.7 %) 1 (1.4 %) 1 (1.4 %) 69
Total 231 (57.75 %) 211 (52.75 %) 161 (40.25 %) 146 (36.5 %) 8 (2.0 %) 43 (10.75 %)
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singular situation with inhabitants of different ethnic ori-
gins and therefore malaria susceptibilities, and with dif-
ferences in local epidemiology, which should be known by 
clinicians who in routine care do not have access to real-
time PCR and thus have a non-negligible risk of overlook-
ing mixed infections. The detection or the anticipation 
of mixed P. vivax/P. falciparum infections is of clinical 
importance because interactions between the different 
species simultaneously infecting the same patient could 
result in significant changes in the course of the infection 
and disease, and thus affect therapeutic strategies. The 
development of rapid diagnostic tests for the detection of 
mixed infections or the systematic and simultaneous use 
of two rapid diagnostic tests allowing: (1) the detection 
of low densities of P. vivax, and, (2) the detection of low 
densities of P. falciparum, to improve mixed infections 
diagnosis and treatment, and further decrease malaria as 
French Guiana moves towards malaria elimination.
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